uPAR Elevated in Bronchial Tissue of Asthma Patients

This article originally appeared here.
Share this content:
uPAR Elevated in Bronchial Tissue of Asthma Patients
uPAR Elevated in Bronchial Tissue of Asthma Patients

FRIDAY, Sept. 23, 2016 (HealthDay News) -- Urokinase plasminogen activator receptor (uPAR) is elevated in patients with asthma, with high uPAR levels linked to severe, non-atopic disease, according to a study published online Sept. 14 in Allergy.

Michael A. Portelli, B.Pharm., Ph.D., from the University of Nottingham in the United Kingdom, and colleagues determined the uPAR expression profile in asthma and control subjects using bronchial biopsies and serum. uPAR levels were examined in nine control and 27 asthmatic bronchial biopsies using immunohistochemistry. In U.K. (129 cases, 39 controls) and Dutch (441 cases, 96 controls) cohorts, soluble cleaved (sc) uPAR levels were determined in serum.

The researchers found that in the bronchial tissue of asthma patients, uPAR was elevated in lamina propria, bronchial epithelial, and airway smooth muscle cells, with uPAR levels correlated between cell types. There were no correlations with disease severity or asthma clinical features. In asthma patients, scuPAR levels were elevated 1.5-fold (P = 0.0008) and there was a correlation between high uPAR serum levels and severe, non-atopic disease.

"This study provides novel data that elevated airway and blood uPAR in asthma is particularly related to severe, non-atopic asthma," the authors write. "The findings warrant further investigation and may provide a therapeutic opportunity for this refractory population."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »